A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 5, 2014, Pages 955-967

  Figg, William D ^a   Monga, Manish ^a   Headlee, Donna ^a   Shah, Avni ^a   Chau, Cindy H ^a   Peer, Cody ^a   Messman, Richard ^a   Elsayed, Yusri A ^a   Murgo, Anthony J ^a   Melillo, Giovanni ^b   Ryan, Qin C ^a   Kalnitskiy, Mikhail ^a   Senderowicz, Adrian M ^c   Hollingshead, Melinda ^a   Arbuck, Susan G ^a   Sausville, Edward A ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

Drug development; Loading dose; Maintenance dose; Perifosine; Phase I

Indexed keywords

ALBUMIN; ALLOPURINOL; ANTIBIOTIC AGENT; BILIRUBIN; COLCHICINE; CREATININE; HEMOGLOBIN; INDOMETACIN; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PERIFOSINE; URIC ACID; PHOSPHORYLCHOLINE;

ADULT; ADVANCED CANCER; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANKLE RADIOGRAPHY; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTHROCENTESIS; ARTICLE; BLADDER SPASM; BONE PAIN; BONE SCINTISCANNING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHONDROCALCINOSIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SOLUBILITY; DYSPEPSIA; DYSPNEA; EDEMA; ELIMINATION HALF-LIFE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL TOXICITY; GOUT; HEADACHE; HICCUP; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; KIDNEY CARCINOMA; KNEE RADIOGRAPHY; LEIOMYOSARCOMA; LOADING DRUG DOSE; LOW BACK PAIN; LYMPHOCYTOPENIA; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLEURA EFFUSION; PNEUMOTHORAX; PROSTATE CANCER; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMATITIS; STREPTOCOCCUS INFECTION; SWEAT GLAND DISEASE; TASTE DISORDER; TREATMENT RESPONSE; TUMOR FLARE; UREMIA; URIC ACID BLOOD LEVEL; URINARY FREQUENCY; VERTIGO; VISUAL DISORDER; VOLUME OF DISTRIBUTION; WEIGHT REDUCTION; WHOLE BODY CT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANOREXIA; AREA UNDER CURVE; DIARRHEA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PHOSPHORYLCHOLINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919730088     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2569-7     Document Type: Article

References (37)

1. Arthur G, Bittman R (1998) The inhibition of cell signaling pathways by antitumor ether lipids. Biochim Biophys Acta Lipids Lipid Metab 1390(1):85-102
2. Herrmann DBJ (1985) Changes in cellular lipid-synthesis of normal and neoplastic-cells during cytolysis induced by alkyl lysophospholipid analogs. J Natl Cancer Inst 75(3):423-430
3. Modolell M, Andreesen R, Pahlke W, Brugger U, Munder PG (1979) Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res 39(11):4681-4686
4. Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ (2001) Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol 49(2):415-419
5. Vehmeyer K, Scheurich P, Eibl H, Unger C (1991) Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin-2. Cell Immunol 137(1):232-238
6. Seewald MJ, Olsen RA, Sehgal I, Melder DC, Modest EJ, Powis G (1990) Inhibition of growth factor-dependent inositol phosphate Ca-2 + signaling by antitumor ether lipid analogs. Cancer Res 50(15):4458-4463
7. Strassheim D, Shafer SH, Phelps SH, Williams CL (2000) Small cell lung carcinoma exhibits greater phospholipase C-beta 1 expression and edelfosine resistance compared with non-small cell lung carcinoma. Cancer Res 60(10):2730-2736
8. Uberall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and protein-kinase-C activity. Cancer Res 51(3):807-812
9. van der Luit AH, Budde M, Ruurs P, Verheij M, van Blitterswijk WJ (2002) Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 277(42):39541-39547
10. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ (1999) Alkyl-lysophospholipids activate the SAPK/JNK signaling pathway and enhance radiation-induced apoptosis. Eur J Cancer 35:S179
11. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM (2002) Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 62(5):1401-1409
12. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2(11):1093-1103
13. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M (2003) Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 14(2):167-173
14. Fensterle J, Aicher B, Seipelt I, Teifel M, Engel J (2014) Current view on the mechanism of action of perifosine in cancer. Anticancer Agents Med Chem 14(4):629-635
15. Naundorf H, Rewasowa EC, Fichtner I, Buttner B, Becker M, Gorlich M (1992) Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives. Breast Cancer Res Treat 23(1-2):87-95
16. Safa O, Parkin SM, Matthew AM, Bibby MC (1997) Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts. Anticancer Res 17(1A):37-43
17. Planting AST, Stoter G, Verweij J (1993) Phase-Ii study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorec-tal- cancer. Eur J Cancer 29A(4):518-519
18. Verweij J, Planting A, Vanderburg M, Stoter G (1992) A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumors. J Cancer Res Clin Oncol 118(8):606-608
19. Verweij J, Krzemieniecki K, Kok T et al (1993) Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult - an EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer 29A(2):208-209
20. Dummer R, Krasovec M, Roger J, Sindermann H, Burg G (1993) Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas-results of a phase-I/II study. J Am Acad Dermatol 29(6):963-970
21. Leonard R, Hardy J, van Tienhoven G et al (2001) Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 19(21):4150-4159
22. Jha TK, Sundar S, Thakur CP et al (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341(24):1795-1800
23. Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J (1997) D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33(3):442-446
24. Crul M, Rosing H, de Klerk GJ et al (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38(12):1615-1621
25. Woo EW, Messmann R, Sausville EA, Figg WD (2001) Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. J Chromatogr B 759(2):247-257
26. Traiser M, Reichert S, Voss A (1998) Current development status of the second generation alkylphosphocholine analog perifosine. Drugs Today 34:67-71
27. Unger C, Berdel W, Hanauske AR, Sindermann H, Engel J, Mross K (2010) First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer 46(5):920-925
28. Van Ummersen L, Binger K, Volkman J et al (2004) A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10(22):7450-7456
29. Posadas EM, Gulley J, Arlen PM et al (2005) A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 4(10):1133-1137
30. Ernst DS, Eisenhauer E, Wainman N et al (2005) Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23(6):569-575
31. Cho DC, Hutson TE, Samlowski W et al (2012) Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 118(24):6055-6062
32. Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC (2012) Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol 158(4):472-480
33. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107(10):4053-4062
34. Richardson PG, Wolf J, Jakubowiak A et al (2011) Perifosine plus bortezomib and dexamethasone in patients with relapsed/ refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 29(32):4243-4249
35. Richardson PG, Nagler A, Ben-Yehuda D, Badros AZ, Hari P, Hajek R, Spicka I, Kaya H, Le Blanc R, Yoon S-S, Kim K, Martinez-Lopez J, Mittelman M, Shpilberg O, Tothova E, Laubach JP, Ghobrial IM, Leiba M, Gatt ME, Sportelli P, Chen M, Anderson KC (2013) Randomized placebo-controlled phase III study of perifosine combined with bortezomib and dexamethasone in relapsed, refractory multiple myeloma patients previously treated with bortezomib. ASH 2013 annual meeting abstract 3189 (poster presentation)
36. Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, Sportelli P, Gardner L, Richards DA (2011) Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 29(33):4394-4400
37. Bendell JC, Senzer NN, Richards DA, Firdaus I, Lockhart AC, Cohn AL, Saleh MN, Gardner LR, Sportelli P (2012) Cathy eng. Results of the X-PECT study: a phase III randomized doubleblind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 30(suppl: abstr LBA3501)